ExodusPoint Capital Management’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

ExodusPoint Capital Management’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-8,851	Closed	-$422K	–	2425
2020 Q2	$422K	Buy	8,851 +4,472	+102%	+$208K	0.01%	1161
2020 Q1	$215K	Buy	+4,379	New	+$223K	0.01%	764
2019 Q4	–	Sell	-9,989	Closed	-$359K	–	2033
2019 Q3	$359K	Sell	9,989 -18,003	-64%	-$703K	0.01%	802
2019 Q2	$870K	Buy	+27,992	New	+$759K	0.03%	298

Other funds holding EIDX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

ExodusPoint Capital Management's EIDX Position: Q3 2020 in Review

ExodusPoint Capital Management sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q3 2020, closing a stake of 8,851 shares — an estimated $422K sold.

ExodusPoint Capital Management first reported a position in EIDX in Q2 2019 and held it in 4 quarters. The position peaked at $870K in Q2 2019. 91 funds tracked by Wall St. Rank hold EIDX as of Q3 2020.

ExodusPoint Capital Management reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
ExodusPoint Capital Management sold 8,851 Eidos Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $422K.
ExodusPoint Capital Management first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2019 and held it in 4 quarters.
ExodusPoint Capital Management's Eidos Therapeutics, Inc. Common Stock position peaked at $870K in Q2 2019.
91 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q3 2020.

Based on ExodusPoint Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.